Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a dose-ranging study of MVT-602 in healthy premenopausal women undergoing controlled ovarian stimulation
2018-001379-20Phase 2Completed
- Sponsor
- Myovant Sciences
- Start
- May 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TAK-448 in female infertility (3 arms), sponsored by Myovant Sciences. Primary endpoint: Maximum change from pre-trigger luteinizing hormone concentration. Started May 2018; status: completed.
02
Drugs
TAK-448
03
Conditions
female infertility
Beyond the preview
Go deeper on 2018-001379-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001379-20.